Total Funding
76
47
Total FundingDebt Financing raised
Growth Score
17 pts
Heat Score
12 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
70755
Proteomedix (an Onconetix company; NASDAQ:ONCO) is a healthcare company whose mission is to transform prostate cancer diagnosis.
Ralph Schiess: CEOPast Role: Proteomedix, Chief Scientific Officer and co-founder
Wilhelm Krek: Co-FoundedPast Role: Friedrich Miescher Institute for Biomedical Research, Professor of Cell Biology
About the Company
Proteomedix (an Onconetix company; NASDAQ:ONCO) is a healthcare company whose mission is to transform prostate cancer diagnosis. The company has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The lead product Proclarix® is a blood based prostate cancer test panel and risk score
currently available in Europe. Proteomedix is located in the Bio-Technopark of Zurich-Schlieren, Switzerland.
